The researchers are doing this study to look at the number of complications that occur immediately after prepectoral breast reconstruction when Acellular Dermal Matrix (ADM) is used compared to when ADM is not used. These complications include infections, the need for Tissue Expander (TE) or implant removal, and other conditions that lead to additional surgery.

Inclusion Criteria:

• Females aged 21-60 years
• Planning to undergo unilateral or bilateral mastectomy, prophylactically or to treat breast cancer
• Planning to undergo immediate two-stage prosthetic breast reconstruction with TE placement as the first stage
• Planning to undergo nipple-sparing or skin-sparing mastectomy
• Adequate mastectomy skin perfusion or adequate perfusion but nonviable mastectomy skin that can be excised (≤4 cm) at the defect margins with otherwise adequate perfusion
• Intraoperative confirmation of prepectoral plane viability by operating physician

Exclusion Criteria:

• History of radiotherapy to the operative breast
• Current smoker
• Non-English speaking patients
• Planning to undergo direct-to-implant reconstruction
• Prior sternotomy

Breast Cancer

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.